Schering Corporation

Pharmacopeia Inc.

Chung-Her Jenh

Paul J Zavodny

Chuan-Chu Chou

Nicholas J Murgolo

William T Windsor

Satwant K Narula

Jan E De Vries

Stephen Tindall

John S Abrams

Mary E Petro

Jon E Silver

Neng-Yang Shih

Joseph A Kozlowski

Stuart B Rosenblum

Douglas Walsh Hobbs

Brian F McGuinness

Seong Heon Kim

Guizhen Dong

Gopinadhan N Anilkumar

Yuefei Shao

Lisa Guise Zawacki

Cangmeng Yang

Carolyn Dilanni Carroll

Changmeng Yang

The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: and the pharmaceutically acceptable salts, solvates and esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.

Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity

A monoclonal antibody is provided which specifically binds to human interleukin-5. Also provided are a hybridoma which produces the monoclonal antibody; complementary DNAs which encode the heavy and light chain variable regions of the monoclonal antibody and CDRs therefrom; humanized monoclonal antibodies; and pharmaceutical compositions comprising the monoclonal antibody or anti-idiotypic antibodies directed against it, humanized monoclonal antibodies, binding fragments, binding compositions or single-chain binding proteins derived from the antibody and a physiologically acceptable carrier.

Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5

Stably-transformed human cell lines containing a reporter gene operatively linked to an IL-4-responsive element are provided. In some embodiments a human Fc,RII IL-4-responsive element is used. In other embodiments a human germline &egr; transcript promoter is used as the responsive element. Also provided are methods for using such transformed cell lines to screen for agonists and/or antagonists of human interleukin-4.

Materials and methods for screening human interleukin-4 antagonists/agonists

Humanized monoclonal antibodies against human interleukin-5

Stably-transformed human cell lines containing a reporter gene operatively linked to an IL-4-responsive element are provided. In some embodiments a human Fc.sub..epsilon. RII IL-4-responsive element is used. In other embodiments a human germline .epsilon. transcript promoter is used as the responsive element. Also provided are methods for using such transformed cell lines to screen for agonists and/or antagonists of human interleukin-4.

Human interleukin-4 antagonist/agonist screens

Growing community of inventors

Annandale, NJ, United States of America

Chung-Her Jenh